Next generation sequencing market forecast to reach $28.59B by 2030

The Business Research Company projects the next generation sequencing market will grow from $16.31 billion in 2026 to $28.59 billion by 2030, driven by precision medicine, oncology diagnostics and wider genomics research. North America led the market in 2025, while Asia-Pacific is expected to post the fastest growth.

Why it matters: - Next generation sequencing is becoming a core tool for genetic analysis, disease research and clinical decision-making. - The market’s expected rise signals more spending on genomics platforms, sequencing reagents and bioinformatics systems. - Growth in precision medicine and oncology diagnostics points to wider use in real-world healthcare.

What happened: - The Business Research Company released a 2026 report on the global next generation sequencing market. - The market is projected to grow from $14.2 billion in 2025 to $16.31 billion in 2026. - The report forecasts the market will reach $28.59 billion by 2030. - The company projects a 15.1% CAGR for the 2026-2030 period. - North America held the largest share of the global market in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - Growth in 2026 is linked to genomics research activity, lower sequencing costs, more molecular diagnostics laboratories, stronger demand for disease-related genetic analysis and better sequencing reagents and tools. - Forecast growth is expected to come from precision medicine initiatives, population genomics investments, oncology diagnostics, faster sequencing technologies and tighter links between sequencing data and clinical decision systems. - The report identifies high-throughput sequencing platforms, clinical diagnostics, AI-based bioinformatics tools, targeted and personalized medicine, and lower-cost workflows as key trends. - Next generation sequencing provides ultra-high throughput, scalability and rapid data processing. - The technology supports detailed analysis of genetic variations tied to disease and other biological phenomena. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also highlights market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, technology analysis and updated graphics and tables. - The company offers a free sample report and the full report through the sample request page and the full market report.

Between the lines: - The forecast suggests sequencing demand is shifting from research-only use toward more routine clinical applications. - The inclusion of AI bioinformatics and clinical decision integration signals a market moving toward software-driven workflows, not just hardware sales. - The regional split implies mature demand in North America and a larger growth runway in Asia-Pacific. - The report’s focus on personalized medicine fits broader healthcare trends toward treatment based on patient-specific genetic data.

What's next: - The market’s next test is whether clinical adoption can keep pace with falling technology costs and rising data-analysis needs. - Wider use in oncology, population genomics and precision medicine could keep the sector on a high-growth path through 2030. - More demand for cost-effective workflows and faster sequencing tools is likely to shape vendor competition.

The bottom line: - Next generation sequencing is moving deeper into clinical care, and that shift is expected to support double-digit market growth through the end of the decade.